Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 96,358,264
  • Shares Outstanding, K 1,306,730
  • Annual Sales, $ 30,390 M
  • Annual Income, $ 13,501 M
  • 36-Month Beta 1.21
  • Price/Sales 3.17
  • Price/Cash Flow 5.85
  • Price/Book 4.61

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.54 +8.24%
on 07/07/17
75.29 -1.46%
on 07/25/17
+2.95 (+4.14%)
since 06/26/17
3-Month
63.76 +16.36%
on 06/16/17
75.29 -1.46%
on 07/25/17
+5.97 (+8.75%)
since 04/26/17
52-Week
63.76 +16.36%
on 06/16/17
82.10 -9.63%
on 08/24/16
-6.86 (-8.46%)
since 07/26/16

Most Recent Stories

More News
Gilead (GILD) Shares Pop on Q2 Earnings and Revenue Beats

Gilead Sciences (GILD) just released its second-quarter financial results, posting non-GAAP diluted earnings of $2.56 and revenues of $7.14 billion.

GILD : 74.19 (+0.61%)
Mylan Receives WHO Prequalification for Generic Sovaldi®

Mylan N.V. (NASDAQ, TASE: MYL), a leading global pharmaceutical company, today announced receipt of approval from the World Health Organization Prequalification of Medicines Program (WHO PQ) of its application...

MYL : 39.19 (+0.95%)
GILD : 74.19 (+0.61%)
Investor Network: Gilead Sciences, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / July 26, 2017 / Gilead Sciences, Inc. (NASDAQ: GILD) will be discussing their earnings results in their Q2 Earnings Call to be held on Wednesday, July 26, 2017 at 4:30 PM Eastern...

GILD : 74.19 (+0.61%)
Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug

Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.

IRWD : 17.10 (+0.35%)
MDCO : 38.33 (-1.03%)
INCY : 137.19 (+2.72%)
GILD : 74.19 (+0.61%)
AMGN : 175.89 (-2.76%)
BIIB : 295.61 (+4.47%)
NKTR : 23.12 (-0.47%)
BioPlus Specialty Pharmacy Releases Updated Version of 'HCV Treatment Path' App for Prescribers; Includes Latest Hepatitis C Medication Guidelines for Vosevi

BioPlus Specialty Pharmacy (BioPlus), one of the nation's leading innovative specialty pharmacies, has released an updated version of the HCV Treatment Path app (version 4.4.0) to keep health care providers...

GILD : 74.19 (+0.61%)
Four Hot Stocks to Watch

Ford Motor Co. (F) : Consumer Discretionary - Automobiles | Reports July 26th, BMO. The Estimize consensus calls for EPS of $.45, one cent higher than the Wall Street consensus and a decrease of 15%...

KO : 45.74 (+1.11%)
F : 11.06 (-1.86%)
GILD : 74.19 (+0.61%)
BA : 233.45 (+9.88%)
Estimize Roundtable: What these experts say would have been a better path to Health Care reform

This week on the Estimize Roundtable, Estimize’s CEO, Leigh Drogen, and SVP of Media, Christine Short, are joined by Joe McCann, CEO and founder of Slingshot Insights, and and Spencer Jakab, Deputy Editor...

PETS : 50.54 (+5.12%)
VRTX : 163.42 (+0.90%)
IBB : 325.90 (+0.65%)
GILD : 74.19 (+0.61%)
BIIB : 295.61 (+4.47%)
Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK

We have three pharma giants that are set to report second-quarter results on Jul 26. Let's see how things are shaping up for this quarter.

JNJ : 130.95 (-0.71%)
LLY : 81.84 (-0.43%)
VRTX : 163.42 (+0.90%)
NVS : 84.85 (+0.77%)
GILD : 74.19 (+0.61%)
GSK : 40.85 (-2.65%)
BIIB : 295.61 (+4.47%)
Can Intercept (ICPT) Beat Estimates this Earnings Season?

Intercept Pharmaceuticals, Inc.'s (ICPT) lead drug Ocaliva's uptake has been encouraging and we expect the company to throw light on its label expansion when it reports second-quarter results.

VRTX : 163.42 (+0.90%)
GILD : 74.19 (+0.61%)
ICPT : 128.82 (+0.03%)
ALXN : 131.07 (+1.33%)
Will Radius Health (RDUS) Disappoint this Earnings Season?

Radius Health Inc. (RDUS) is expected to throw light on the launch and uptake of its newly approved drug Tymlos when it reports second-quarter results.

RDUS : 43.37 (+1.00%)
VRTX : 163.42 (+0.90%)
GILD : 74.19 (+0.61%)
ICPT : 128.82 (+0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections...

See More

Support & Resistance

2nd Resistance Point 74.68
1st Resistance Point 74.43
Last Price 74.19
1st Support Level 73.78
2nd Support Level 73.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.